MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe last decade has witnessed significant advancements in our understanding of how small noncoding RNAs, such as microRNAs (miRNAs), regulate disease progression. One such miRNA, miR-221, has been shown to play a key role in the progression of liver fibrosis, a common feature of most liver diseases. Many reports have demonstrated the upregulation of miR-221 in liver fibrosis caused by multiple etiologies such as viral infections and nonalcoholic steatohepatitis. Inhibition of miR-221 via different strategies has shown promising results in terms of the suppression of fibrogenic gene signatures in vitro, as well as in vivo, in independent mouse models of liver fibrosis. In addition, miR-221 has also been suggested as a noninvasive serum biomarker for liver fibrosis and cirrhosis. In this review, we discuss the biology of miR-221, its significance and use as a biomarker during progression of liver fibrosis, and finally, potential and robust approaches that can be utilized to suppress liver fibrosis via inhibition of miR-221.
CitationCells. 2020 Jul 23;9(8):1767. doi: 10.3390/cells9081767.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.
- Authors: Wang Y, Liu Z, Zou W, Hong H, Fang H, Tong W
- Issue date: 2015
- MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease.
- Authors: Takeuchi-Yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T, Matsumoto M
- Issue date: 2016 Sep 6
- miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
- Authors: Rodrigues PM, Afonso MB, Simão AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, Castro RE
- Issue date: 2017 Apr 13
- A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis.
- Authors: Liu J, Xiao Y, Wu X, Jiang L, Yang S, Ding Z, Fang Z, Hua H, Kirby MS, Shou J
- Issue date: 2018 Mar 9
- MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes.
- Authors: Elemeery MN, Mohamed MA, Madkour MA, Shamseya MM, Issa NM, Badr AN, Ghareeb DA, Pan CH
- Issue date: 2019 Nov 14